Navigation Links
Flunitrazepam ELISA Kit, Single from Bio-Quant Inc.

ProductsFlunitrazepam ELISA Kit, Single from Bio-Quant Inc.
Company Bio-Quant Inc.
Item Flunitrazepam ELISA Kit, Single
Price $200.00
Description Request Info
Info Bio-Quant Inc.Bio-Quant Inc.
6191 Cornerstone Court East, Suite 101
San Diego, CA 92121
Customer Service: (858) 450-0048
Fax Number: (858) 587-2131
Web Site: http://www.bio-quant.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Free Activin A ELISA Kit from Diagnostic Systems Laboratories, Inc.
2. Free Activin AB ELISA Kit from Diagnostic Systems Laboratories, Inc.
3. Free Activin B ELISA Kit from Diagnostic Systems Laboratories, Inc.
4. HIV-1 p24 ELISA Kit, Alliance (480 Tests) from PerkinElmer
5. Porcine Leptin ELISA Kit from Diagnostic Systems Laboratories, Inc.
6. Equine TNF alpha ELISA development Kit, Screening Set from Endogen
7. Staccato Sciclone ELISA Station from Caliper Life Sciences
8. Telomerase ELISA Assay Kit, TRAPEZE from CHEMICON
9. Nuclear Matrix Protein ELISA Kit from Calbiochem
10. Rat TRACP 5b ELISA Kit, TRAPTM from IDS Ltd
11. ELISA Antibody Diluent-Rabbit Polyclonal from AbD Serotec
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products:
(Date:7/31/2015)... The 10 th International Conference on Genomics (ICG-10, ... in Shenzhen , China ... anniversary this year. Since its inauguration in 2006, ICG ... in the ,omics, fields, and is one of the most ... focuses on recent breakthroughs and advances in ,omics, research that ...
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
(Date:7/21/2015)... YORK , July 21, 2015 ... systems, as seen in the recent U.S. Office ... a solution to the infosec conundrum, but developers ... is stored. To address this dilemma, Biometrics-as-a-Service provider ... its Biometric Tokenization SDK for third party integration. ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... techniques allow biologists to create quantitative, three-dimensional descriptions of ... the microscope. For example, they can accurately estimate ... length of a mass of blood vessels, or the ... of the brain. A new book from ...
... The injection of a tiny capsule containing heat-generating cells ... abdominal fat and initially lose about 20 percent of belly ... study were surprised to see that the injected cells even ... thermogenic cells, which use fat to generate heat. ...
... sources of information, <a target="_blank" href="http://en.wikipedia.org/wiki/Nucleic_acid_sequence,">DNA sequences ... To identify, proof, and discard compromised molecular data ... scientific endeavor - one that everyone generating sequence ... the sequences for research purposes. "Many researchers ...
Cached Biology News:Study in mice discovers injection of heat-generating cells reduces belly fat 2Study in mice discovers injection of heat-generating cells reduces belly fat 3Study in mice discovers injection of heat-generating cells reduces belly fat 4DNA sequences need quality time too - guidelines for quality control published 2
(Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3